Melanie Uhde1, Mary Ajamian1, Xueting Li1, Gary P Wormser2, Adriana Marques3, Armin Alaedini1. 1. Department of Medicine, Columbia University Medical Center, New York. 2. Division of Infectious Diseases, Department of Medicine, New York Medical College, Valhalla, New York. 3. Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
Abstract
BACKGROUND: Infection with Borrelia burgdorferi, the causative agent of Lyme disease, triggers host immune responses that affect the clinical outcome and are a source of biomarkers with diagnostic utility. Although adaptive immunity to B. burgdorferi has been extensively characterized, considerably less information is available about the development of innate acute-phase responses in Lyme disease. Our aim in this study was to evaluate the expression of C-reactive protein (CRP) and serum amyloid A (SAA), the prototype acute-phase response proteins, in the context of the varying manifestations associated with Lyme borreliosis. METHODS: Circulating concentrations of CRP and SAA in patients with a range of early to late objective manifestations of Lyme disease and in individuals with post-treatment Lyme disease syndrome were compared with those in healthy control groups. RESULTS: CRP and SAA levels were significantly elevated in early localized and early disseminated Lyme disease but not in the later stages of active infection. Levels of CRP, but not SAA, were also found to be significantly increased in patients with antibiotic-refractory Lyme arthritis and in those with post-treatment Lyme disease syndrome. CONCLUSIONS: These findings indicate that circulating CRP and SAA levels are highest when the concentration of spirochetes is greatest in skin and/or blood and that levels decline after the dissemination of the organism to extracutaneous sites in subsequent stages of infection. The data also suggest that antibiotic-refractory Lyme arthritis and post-treatment Lyme disease syndrome are associated with elevated CRP responses that are driven by inflammatory mechanisms distinct from those in active infection.
BACKGROUND:Infection with Borrelia burgdorferi, the causative agent of Lyme disease, triggers host immune responses that affect the clinical outcome and are a source of biomarkers with diagnostic utility. Although adaptive immunity to B. burgdorferi has been extensively characterized, considerably less information is available about the development of innate acute-phase responses in Lyme disease. Our aim in this study was to evaluate the expression of C-reactive protein (CRP) and serum amyloid A (SAA), the prototype acute-phase response proteins, in the context of the varying manifestations associated with Lyme borreliosis. METHODS: Circulating concentrations of CRP and SAA in patients with a range of early to late objective manifestations of Lyme disease and in individuals with post-treatment Lyme disease syndrome were compared with those in healthy control groups. RESULTS:CRP and SAA levels were significantly elevated in early localized and early disseminated Lyme disease but not in the later stages of active infection. Levels of CRP, but not SAA, were also found to be significantly increased in patients with antibiotic-refractory Lyme arthritis and in those with post-treatment Lyme disease syndrome. CONCLUSIONS: These findings indicate that circulating CRP and SAA levels are highest when the concentration of spirochetes is greatest in skin and/or blood and that levels decline after the dissemination of the organism to extracutaneous sites in subsequent stages of infection. The data also suggest that antibiotic-refractory Lyme arthritis and post-treatment Lyme disease syndrome are associated with elevated CRP responses that are driven by inflammatory mechanisms distinct from those in active infection.
Authors: Henry M Feder; Barbara J B Johnson; Susan O'Connell; Eugene D Shapiro; Allen C Steere; Gary P Wormser; W A Agger; H Artsob; P Auwaerter; J S Dumler; J S Bakken; L K Bockenstedt; J Green; R J Dattwyler; J Munoz; R B Nadelman; I Schwartz; T Draper; E McSweegan; J J Halperin; M S Klempner; P J Krause; P Mead; M Morshed; R Porwancher; J D Radolf; R P Smith; S Sood; A Weinstein; S J Wong; L Zemel Journal: N Engl J Med Date: 2007-10-04 Impact factor: 91.245
Authors: Matthew D Milewski; Aristides I Cruz; Christopher P Miller; Ashley T Peterson; Brian G Smith Journal: J Bone Joint Surg Am Date: 2011-02-02 Impact factor: 5.284
Authors: Abhishek Chandra; Gary P Wormser; Mark S Klempner; Richard P Trevino; Mary K Crow; Norman Latov; Armin Alaedini Journal: Brain Behav Immun Date: 2010-03-18 Impact factor: 7.217
Authors: Kevin S Tang; Mark S Klempner; Gary P Wormser; Adriana R Marques; Armin Alaedini Journal: Clin Infect Dis Date: 2015-07-28 Impact factor: 9.079
Authors: Melanie Uhde; Alyssa Indart; Brian A Fallon; Gary P Wormser; Adriana R Marques; Suzanne D Vernon; Armin Alaedini Journal: Clin Infect Dis Date: 2018-09-28 Impact factor: 9.079
Authors: Yong Zhou; Shizhen Qin; Mingjuan Sun; Li Tang; Xiaowei Yan; Taek-Kyun Kim; Juan Caballero; Gustavo Glusman; Mary E Brunkow; Mark J Soloski; Alison W Rebman; Carol Scavarda; Denise Cooper; Gilbert S Omenn; Robert L Moritz; Gary P Wormser; Nathan D Price; John N Aucott; Leroy Hood Journal: J Proteome Res Date: 2019-11-01 Impact factor: 5.370
Authors: Jason R Bobe; Brandon L Jutras; Elizabeth J Horn; Monica E Embers; Allison Bailey; Robert L Moritz; Ying Zhang; Mark J Soloski; Richard S Ostfeld; Richard T Marconi; John Aucott; Avi Ma'ayan; Felicia Keesing; Kim Lewis; Choukri Ben Mamoun; Alison W Rebman; Mecaila E McClune; Edward B Breitschwerdt; Panga Jaipal Reddy; Ricardo Maggi; Frank Yang; Bennett Nemser; Aydogan Ozcan; Omai Garner; Dino Di Carlo; Zachary Ballard; Hyou-Arm Joung; Albert Garcia-Romeu; Roland R Griffiths; Nicole Baumgarth; Brian A Fallon Journal: Front Med (Lausanne) Date: 2021-08-18